Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DPIR35
|
|||
| Drug Name |
OMP-131R10
|
|||
| Drug Type |
Antibody
|
|||
| Indication | Solid tumour/cancer [ICD-11: 2A00-2F9Z; ICD-10: C00-D48; ICD-9: 140-199] | Phase 1 | [1] | |
| Company |
OncoMed
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | R-spondin-3 (RSPO3) | Target Info | . | [2] |
| KEGG Pathway | Wnt signaling pathway | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT02482441) A Phase 1a/b Dose Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of OMP-131R10. U.S. National Institutes of Health. | |||
| REF 2 | Targeting the Wnt signaling pathway through R-spondin 3 identifies an anti-fibrosis treatment strategy for multiple organs. PLoS One. 2020 Mar 11;15(3):e0229445. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.